Myriad details findings from EndoPredict study in early stage breast cancer

Myriad Genetics announced that the EndoPredict test identifies women with early-stage breast cancer who can safely forgo extended endocrine therapy five years after diagnosis. The newly published study assessed the ability of the EndoPredict test to predict early distant recurrence and late recurrence of breast cancer, according to nodal status. The analysis included 1,702 patients with early-stage ER-positive, HER2-negative breast cancer who received five years of endocrine therapy alone. Overall, 62.6 percent of patients had low EndoPredict scores. Women with low EndoPredict scores had a statistically significantly reduced risk of distant recurrence compared to those with high scores Importantly, EndoPredict was highly predictive of both early and late distant recurrence in both node-negative and node-positive women, Myriad said.
https://thefly.com/landingPageNews.php?id=2906623